BMRN Q2 2025 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$825M+15.9% YoY

Gross Profit

$675M81.8% margin

Operating Income

$277M33.5% margin

Net Income

$241M29.1% margin

EPS (Diluted)

$1.23

QoQ Revenue Growth

+10.8%

Cash Flow

Operating Cash Flow

$185M

Free Cash Flow

$168M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$7.5B

Total Liabilities

$1.4B

Stockholders' Equity

$6.0B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$825M	$712M	+15.9%
Gross Profit	$675M	$582M	+16.1%
Operating Income	$277M	$120M	+129.9%
Net Income	$241M	$107M	+124.4%

Revenue Segments

Product

$813M98%

Royalty And Other

$12M2%